<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Percutaneous coronary intervention after fibrinolysis for acute ST-elevation myocardial infarction
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Percutaneous coronary intervention after fibrinolysis for acute ST-elevation myocardial infarction
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Percutaneous coronary intervention after fibrinolysis for acute ST-elevation myocardial infarction
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher P Cannon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donald Cutlip, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 20, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the setting of acute ST-elevation myocardial infarction (STEMI), the primary goal of percutaneous coronary intervention (PCI) or fibrinolysis is to reestablish patency of the affected coronary artery and thereby improve perfusion of the myocardium. The preferred reperfusion therapy in many patients is primary PCI if it can be delivered in a timely manner; if not, fibrinolytic therapy is given [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/80.html" rel="external">
          "Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"
         </a>
         .)
        </p>
        <p>
         For patients who have been treated with fibrinolytic therapy, subsequent PCI may be needed for the following reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To achieve reperfusion if there is apparent failure of fibrinolysis, often due to a residual clot. (See
         <a class="local">
          'Failed fibrinolysis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To treat significant residual and hemodynamically important stenosis. This pertains to the infarct-related artery and flow-limiting stenoses in noninfarct arteries. (See
         <a class="local">
          'Pharmacoinvasive strategy'
         </a>
         below and
         <a class="local">
          'Angina and inducible ischemia'
         </a>
         below and
         <a class="local">
          'Total Occlusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         This topic outlines
         <strong>
         </strong>
         the clinical situations in which PCI is used after fibrinolytic therapy. The principal discussion of failed fibrinolysis or threatened reocclusion is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/91.html" rel="external">
          "Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction"
         </a>
         .)
        </p>
        <p>
         Other related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/55.html" rel="external">
          "Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/66.html" rel="external">
          "Overview of the acute management of ST-elevation myocardial infarction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/80.html" rel="external">
          "Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15358.html" rel="external">
          "Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Periprocedural management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          FAILED FIBRINOLYSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fibrinolysis may fail either from the beginning (primary failure) or after apparent early success. The terms used for urgent PCI after fibrinolysis are "rescue or salvage" and "threatened occlusion," respectively. If failed fibrinolysis is suspected, urgent PCI should be attempted. The efficacy of and recommendations for PCI for failed fibrinolysis are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/91.html" rel="external">
          "Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction"
         </a>
         .)
        </p>
        <p>
         Primary failure is clinically suspected by persistent, severe, or worsening chest pain; hemodynamic instability; or electrocardiographic (ECG) markers of persistent ischemia. We consider less than 50 percent resolution in the ECG lead showing the greatest degree of ST-segment elevation at presentation as a marker of persistent ischemia and likely failure of fibrinolysis [
         <a href="#rid2">
          2
         </a>
         ]. When these patients are taken for angiography, primary failure is associated with persistent occlusion of the infarct-related artery (Thrombosis in Myocardial Infarction [TIMI] grade 0/1)  (
         <a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">
          table 1
         </a>
         ). A discussion of the TIMI grade is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/91.html" rel="external">
          "Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction", section on 'Importance of restoration of normal flow'
         </a>
         .)
        </p>
        <p>
         Threatened reocclusion of the infarct-related artery is characterized by the development of early recurrent ischemia after apparently successful fibrinolysis. Thrombotic reocclusion can be manifested by recurrent ST-segment elevation, recurrent chest pain, and/or evidence of reinfarction, generally with a second troponin rise. After apparently successful fibrinolysis by either clinical or angiographic criteria, early recurrence of ischemia or ST-segment shifts (eg, threatened reocclusion) has been observed in 20 to 30 percent of patients [
         <a href="#rid3">
          3,4
         </a>
         ], thrombotic coronary reocclusion in 5 to 15 percent [
         <a href="#rid5">
          5-7
         </a>
         ], and reinfarction in 3 to 5 percent [
         <a href="#rid8">
          8-11
         </a>
         ].
        </p>
        <p>
         In two reviews of almost 76,000 patients from GUSTO-I, GUSTO-III, and the TIMI and InTIME II trials, reinfarction occurred in 4.3 percent of patients at a median of two to four days after fibrinolytic therapy [
         <a href="#rid8">
          8,9
         </a>
         ]. The patients with reinfarction had a higher overall mortality rate at 30 days (11.3 to 16.4 versus 3.5 to 6.2 percent without reinfarction). The mortality associated with reinfarction can be markedly reduced with PCI during the index hospitalization [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Hemodynamic instability and cardiogenic shock
         </span>
         <span class="headingEndMark">
          —
         </span>
         An early invasive approach after fibrinolysis is the treatment of choice for patients with cardiogenic shock. This approach may also improve outcomes in other high-risk patients, such as those with moderate heart failure or pulmonary edema (Killip class II and III)  (
         <a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid12">
          12-15
         </a>
         ].
        </p>
        <p>
         The efficacy of primary revascularization in patients with cardiogenic shock following an acute MI was first suggested in an observational study [
         <a href="#rid14">
          14
         </a>
         ] and then demonstrated in the SHOCK trial in which 49 percent of patients in the revascularization group had initially been treated with fibrinolytic therapy [
         <a href="#rid13">
          13
         </a>
         ]. The benefit was limited to patients under age 75, of whom 20 lives were saved per 100 treated at six months. The details of this trial are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/83.html" rel="external">
          "Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction"
         </a>
         .)
        </p>
        <p>
         In comparison with primary PCI, fibrinolysis alone is relatively ineffective in patients with cardiogenic shock unless coronary perfusion pressure is increased by vasopressors and/or intraaortic balloon counterpulsation. Thus, patients admitted to hospitals without facilities for revascularization should be immediately transferred to a tertiary care center with intent for early revascularization; they can be treated with fibrinolysis (if indicated) and insertion of an intraaortic balloon pump (if available) if there is a delay or the tertiary care center is far away. (See
         <a class="medical medical_review" href="/z/d/html/83.html" rel="external">
          "Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          FACILITATED PCI (WITH FIBRINOLYTIC THERAPY)
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not recommend facilitated PCI (also referred to as adjunctive fibrinolytic therapy) with full-dose fibrinolytic therapy, half-dose fibrinolytic therapy, or half-dose fibrinolytic therapy with a glycoprotein IIb/IIIa inhibitor [
         <a href="#rid16">
          16-19
         </a>
         ]. Facilitated PCI refers to pharmacologic therapy just prior to planned primary PCI for STEMI in an attempt to achieve an open infarct-related artery before arrival in the catheterization laboratory. (See
         <a class="medical medical_review" href="/z/d/html/72.html" rel="external">
          "Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome", section on 'Transfer from a non-PCI center'
         </a>
         .)
        </p>
        <p>
         A 2006 meta-analysis included six trials of facilitated PCI with fibrinolytic therapy, involving almost 3000 patients [
         <a href="#rid20">
          20
         </a>
         ]. Approximately 75 percent of the patients came from the ASSENT-4 and PACT trials. Despite the initial early perfusion benefit, facilitated PCI was associated with significant increases in short-term rates of mortality (6 versus 4 percent), nonfatal reinfarction (4 versus 2 percent), urgent target vessel revascularization (5 versus 1 percent), and stroke (1.6 versus 0.3 percent); and a nonsignificant increase in major bleeding (7 versus 5 percent).
        </p>
        <p>
         In addition, we do not recommend the use of intracoronary fibrinolytic therapy shortly after reperfusion. One study of low-dose
         <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">
          alteplase
         </a>
         found no benefit and potential harm [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1293488">
         <span class="h1">
          PHARMACOINVASIVE STRATEGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A pharmacoinvasive approach refers to the routine administration of a pharmacologic agent (eg, fibrinolytic therapy) prior to planned PCI for STEMI in an attempt to achieve an open infarct-related artery before arrival to the catheterization laboratory, which must be delayed for some reason. We use this approach in most patients treated with fibrinolytic therapy. This issue is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/80.html" rel="external">
          "Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"
         </a>
         .)
        </p>
        <p>
         While we recommend diagnostic coronary angiography for most patients who receive fibrinolytic therapy, we recognize that some patients at very low risk will be managed with a conservative strategy of "watchful waiting" with monitoring for spontaneous recurrent ischemia and, if not seen, stress testing should be performed to evaluate for provocable ischemia. If ischemia is present, patients should undergo angiography and revascularization.
        </p>
        <p>
         This approach is generally used prior to transfer of a STEMI patient from a noninterventional hospital to one with PCI capability when the anticipated delay to PCI is not acceptable (see
         <a class="medical medical_review" href="/z/d/html/72.html" rel="external">
          "Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome", section on 'Definitions'
         </a>
         ). The patient is then taken to the interventional lab within 2 to 24 hours of presentation for angiogram and planned PCI.
        </p>
        <p>
         While the benefit after 24 hours may be very small, the potential need for angiography and PCI may be assessed with stress testing.
        </p>
        <p>
         The pharmacoinvasive strategy differs slightly from the above "facilitated PCI" in that the latter has PCI occurring within an hour of the initial pharmacotherapy, which, as described above, is harmful. (See
         <a class="local">
          'Facilitated PCI (with fibrinolytic therapy)'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4083390144">
         <span class="h1">
          PATIENTS TREATED AT NON-PCI HOSPITALS OR IN AN AMBULANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unstable patients treated with fibrinolytic therapy at a non-PCI hospital or in an ambulance should be moved as quickly as possible to a PCI-capable hospital. We usually advise transfer within a 6- to 24-hour time window for stable patients at higher risk, such as those with anterior MI or a large inferior MI, and who have received fibrinolytic therapy at a non-PCI hospital. In the TRANSFER-AMI study, immediate fibrinolysis and transfer for PCI within six hours versus transfer and PCI within approximately 24 hours led to a lower composite death, MI, recurrent ischemia, heart failure, or cardiogenic shock at 30 days (11.0 versus
         <em>
         </em>
         17.2 percent; p = 0.004) [
         <a href="#rid22">
          22
         </a>
         ]. Similarly, CARESS-in-AMI found that patients transferred for PCI within 12 hours of half-dose
         <a class="drug drug_general" data-topicid="9857" href="/z/d/drug information/9857.html" rel="external">
          reteplase
         </a>
         and abciximab had lower composite mortality, MI, or refractory ischemia at 30 days than patients in the standard care group (4.4 versus
         <em>
         </em>
         10.7 percent; p = 0.004) [
         <a href="#rid23">
          23
         </a>
         ]. This issue is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/80.html" rel="external">
          "Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"
         </a>
         .)
        </p>
        <p>
         If a patient could not be transferred in the above time window, later transfer is reasonable.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          ANGINA AND INDUCIBLE ISCHEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For lower-risk patients who did not undergo PCI after fibrinolysis and who have been clinically stable, PCI (or coronary artery bypass graft surgery [CABG]) is recommended for recurrent angina or asymptomatic residual ischemia, which are typically documented with stress testing [
         <a href="#rid24">
          24,25
         </a>
         ]. A predischarge low-level exercise tolerance test is recommended for all patients who have not undergone coronary revascularization with PCI or CABG. (See
         <a class="medical medical_review" href="/z/d/html/66.html" rel="external">
          "Overview of the acute management of ST-elevation myocardial infarction"
         </a>
         .)
        </p>
        <p>
         The efficacy of revascularization in patients with recurrent or residual ischemia was evaluated in the DANAMI trial [
         <a href="#rid26">
          26
         </a>
         ]. This trial consisted of 1008 patients with an acute STEMI who were treated with a fibrinolytic agent and had developed either spontaneous symptomatic angina or inducible post-MI ischemia on a predischarge exercise test; the patients were randomly assigned to conservative therapy or revascularization with PCI or CABG 2 to 10 weeks after the MI. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At one, two, and four years, the primary endpoints (eg, mortality, reinfarction, or admission for unstable angina) occurred significantly less frequently in the invasive group compared with those treated conservatively (15 versus 30 percent, 24 versus 37 percent, and 32 versus 44 percent, respectively)  (
         <a class="graphic graphic_figure graphicRef58727" href="/z/d/graphic/58727.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefit was due to a lower rate of reinfarction and admission for unstable angina; mortality after a median follow-up of 2.4 years was equivalent in both groups  (
         <a class="graphic graphic_figure graphicRef58727" href="/z/d/graphic/58727.html" rel="external">
          figure 1
         </a>
         ). With an absolute reduction in MI of 13 percent and overall reduction in cardiovascular events of 15 percent, the number needed to be treated with an invasive strategy to prevent a cardiovascular event would be six to seven patients.
        </p>
        <p>
        </p>
        <p>
         Other indirect evidence for benefit of late PCI in patients with ischemia comes from the SWISSI II trial, which randomly assigned 201 asymptomatic patients with silent myocardial ischemia after both STEMI (most were treated with fibrinolytic therapy) and non-ST-elevation MI to either PCI or intensive antiischemic drug therapy [
         <a href="#rid27">
          27
         </a>
         ]. During a mean follow-up of 10.2 years, there was a significant reduction in major adverse cardiovascular outcomes in the PCI group (adjusted hazard ratio 0.33, 95% CI 0.20-0.55).
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          TOTAL OCCLUSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         It has been suggested that achieving patency in an asymptomatic, occluded, infarct-related artery hours to days after the acute event may have a beneficial effect by mechanisms other than myocardial salvage, such as prevention of ventricular remodeling [
         <a href="#rid28">
          28,29
         </a>
         ]. Multiple small studies and one large randomized trial (OAT trial) have found that PCI 3 to 28 days after STEMI in asymptomatic patients does not lead to improvement in the rates of death, MI, stroke, heart failure, or revascularization compared with medical therapy [
         <a href="#rid30">
          30-32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          RECOMMENDATIONS OF OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our recommendations are generally consistent with those from the American College of Cardiology Foundation/American Heart Association and the European Society of Cardiology [
         <a href="#rid2">
          2,33,34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2521584600">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">
          "Society guideline links: ST-elevation myocardial infarction (STEMI)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3371858171">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15786.html" rel="external">
          "Patient education: Heart attack (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16327.html" rel="external">
          "Patient education: Heart attack recovery (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16334.html" rel="external">
          "Patient education: Medicines after a heart attack (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/3447.html" rel="external">
          "Patient education: Heart attack (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/3430.html" rel="external">
          "Patient education: Heart attack recovery (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of PCI in patients undergoing fibrinolysis
         </strong>
         – Primary percutaneous coronary intervention (PCI) is the recommended reperfusion strategy for most patients with acute ST-elevation myocardial infarction (STEMI). However, many patients are not able to receive primary PCI in a timely manner. In such patients, fibrinolytic therapy has been shown to be of benefit compared with no reperfusion therapy. (See
         <a class="medical medical_review" href="/z/d/html/72.html" rel="external">
          "Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/55.html" rel="external">
          "Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with signs of recurrent ischemia after fibrinolysis for STEMI
         </strong>
         – Recommendations for the management of patients treated with fibrinolysis in whom there is evidence of either primary failure of fibrinolytic therapy (such as ongoing ischemic chest pain or less than 50 percent resolution of the initial ST-segment elevation on electrocardiogram) or threatened reocclusion are found elsewhere. (See
         <a class="local">
          'Failed fibrinolysis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/91.html" rel="external">
          "Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83.html" rel="external">
          "Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who are stable after fibrinolysis for STEMI
         </strong>
         – In stable STEMI patients who have received fibrinolysis, we make the following recommendations:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          PCI within two hours of fibrinolysis
         </strong>
         – We recommend
         <strong>
          not
         </strong>
         performing planned PCI within the first two hours (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). This is known as "facilitated PCI" and leads to worse outcomes. (See
         <a class="local">
          'Facilitated PCI (with fibrinolytic therapy)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          PCI after fibrinolysis
         </strong>
         – For most patients, we recommend coronary angiography with an intent to perform PCI of the infarct-related artery rather than a strategy of PCI for ischemia only (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). This is referred to as the "pharmacoinvasive approach." The optimal timing of routine angiography and possible PCI has not been determined. We believe it should be performed within 3 to 24 hours of initial fibrinolysis. (See
         <a class="local">
          'Pharmacoinvasive strategy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         While we recommend diagnostic coronary angiography for most patients who receive fibrinolytic therapy, we recognize that some patients at very low risk will be managed with a conservative strategy of "watchful waiting" with monitoring for spontaneous recurrent ischemia and, if not seen, stress testing should be performed to evaluate for provocable ischemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If ischemia is present, we recommend prompt coronary arteriography followed by PCI or coronary artery bypass graft surgery (based on anatomic considerations), as opposed to a trial of medical therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Angina and inducible ischemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For stable patients without
         <strong>
         </strong>
         evidence of either spontaneous or significant provocable ischemia, and who are subsequently (after 24 hours) found to have an occluded infarct-related artery, PCI is not typically necessary. (See
         <a class="local">
          'Total Occlusion'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer A, Krucoff MW, Klootwijk P, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998; 31:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990; 82:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003; 42:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbash GI, Birnbaum Y, Bogaerts K, et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. Circulation 2001; 103:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dönges K, Schiele R, Gitt A, et al. Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]). Am J Cardiol 2001; 87:1039.
          </a>
         </li>
         <li class="breakAll">
          www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger PB, Holmes DR Jr, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation 1997; 96:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rott D, Behar S, Leor J, et al. Effect on survival of acute myocardial infarction in Killip classes II or III patients undergoing invasive coronary procedures. Am J Cardiol 2001; 88:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000; 36:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358:2205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 2004; 291:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone GW, Gersh BJ. Facilitated angioplasty: paradise lost. Lancet 2006; 367:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCartney PJ, Maznyczka AM, Eteiba H, et al. Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. J Am Coll Cardiol 2020; 75:1406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360:2705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 371:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madsen JK, Grande P, Saunamäki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997; 96:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 2007; 297:1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim CB, Braunwald E. Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation 1993; 88:2426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pizzetti G, Belotti G, Margonato A, et al. Coronary recanalization by elective angioplasty prevents ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol 1996; 28:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topol EJ, Califf RM, Vandormael M, et al. A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. Circulation 1992; 85:2090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousef ZR, Redwood SR, Bucknall CA, et al. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). J Am Coll Cardiol 2002; 40:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006; 355:2395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35:2541.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 53 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12517460" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23247304" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9799205" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9525547" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8232430" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2956516" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2394002" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11551872" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12849652" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181469" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11348599" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11348599" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10460813" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9236426" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11564383" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect on survival of acute myocardial infarction in Killip classes II or III patients undergoing invasive coronary procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11079647" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18499565" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Facilitated PCI in patients with ST-elevation myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14982910" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16488779" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Facilitated angioplasty: paradise lost.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16488801" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32216909" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19553646" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Routine early angioplasty after fibrinolysis for acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18280326" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18071078" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22064601" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9264478" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488963" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8222135" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8837557" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Coronary recanalization by elective angioplasty prevents ventricular dilation after anterior myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1591828" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12225709" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17105759" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Coronary intervention for persistent occlusion after myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22922416" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25173339" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
